Abstract
Imiquimod is an immune response-modifying agent that demonstrates potent antiviral and antitumour activity. Although its use has been approved by the FDA (Food and Drug Administration) in the treatment of external genital and perianal warts, actinic keratosis on the face or scalp and superficial basal cell carcinomas, it has recently been tried to treat different types of dermatological diseases including molluscum contagiosum, herpes simplex, melanoma, T-cell lymphoma. Side effects of imiquimod are erythema, itching, burning, crusting, and rarely cytokine-release syndrome, exacerbation of inflammatory skin conditions. In this review, the structure of imiquimod, mechanism of action and its usage in the treatment of different skin diseases are discussed.
Keywords: Imiquimod, skin diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Imiquimod
Volume: 6 Issue: 3
Author(s): Idil Unal and Ilgen Ertam
Affiliation:
Keywords: Imiquimod, skin diseases
Abstract: Imiquimod is an immune response-modifying agent that demonstrates potent antiviral and antitumour activity. Although its use has been approved by the FDA (Food and Drug Administration) in the treatment of external genital and perianal warts, actinic keratosis on the face or scalp and superficial basal cell carcinomas, it has recently been tried to treat different types of dermatological diseases including molluscum contagiosum, herpes simplex, melanoma, T-cell lymphoma. Side effects of imiquimod are erythema, itching, burning, crusting, and rarely cytokine-release syndrome, exacerbation of inflammatory skin conditions. In this review, the structure of imiquimod, mechanism of action and its usage in the treatment of different skin diseases are discussed.
Export Options
About this article
Cite this article as:
Idil Unal and Ilgen Ertam , Imiquimod, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (3) . https://dx.doi.org/10.2174/187152307781368265
DOI https://dx.doi.org/10.2174/187152307781368265 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identification of Prognostic Biomarkers in Papillary Thyroid Cancer and
Developing Non-Invasive Diagnostic Models Through Integrated Bioinformatics
Analysis
MicroRNA SDH Genes: From Glomic Tumours to Pheochromocytomas
Current Hypertension Reviews CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets Functional Evaluation of Neural Stem Cell Differentiation by Single Cell Calcium Imaging
Current Stem Cell Research & Therapy Pro-Oxidative Action of Polyphenols as Action Mechanism for their Pro-Apoptotic Activity
Anti-Cancer Agents in Medicinal Chemistry Differentiated Thyroid Carcinoma and Intestinal Polyposis Syndromes
Endocrine, Metabolic & Immune Disorders - Drug Targets Screening and Identification of Differentially Expressed Genes Between Diabetic Nephropathy Glomerular and Normal Glomerular via Bioinformatics Technology
Combinatorial Chemistry & High Throughput Screening Celecoxib Upregulates Multidrug Resistance Proteins in Colon Cancer: Lack of Synergy with Standard Chemotherapy
Current Cancer Drug Targets Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence
Current Diabetes Reviews Chemokines and Chemokine Receptors Blockers as New Drugs for the Treatment of Chronic Obstructive Pulmonary Disease
Current Medicinal Chemistry Protein kinases and the Hypoxia-Inducible Factor-1, two switches in angiogenesis
Current Pharmaceutical Design Xanthohumol, a Prenylated Chalcone Derived from Hops, Suppresses Cancer Cell Invasion through Inhibiting the Expression of CXCR4 Chemokine Receptor
Current Molecular Medicine Transglutaminase-Mediated Activation of Nuclear Transcription Factor-κB in Cancer Cells: A New Therapeutic Opportunity
Current Cancer Drug Targets Increased Tumor Oxygenation and Drug Uptake During Anti-Angiogenic Weekly Low Dose Cyclophosphamide Enhances the Anti-Tumor Effect of Weekly Tirapazamine (Supplementry Material)
Current Cancer Drug Targets Bringing Light into the Diagnosis of Skin Disorders - Short Review on Laser Induced Fluorescence Spectroscopy and Optical Coherence Tomography in Dermatology
Current Medical Imaging Studies of p53 Tumor Suppression Activity in Mouse Models
Current Genomics The link between Hepatic Vitamin A Metabolism and Nonalcoholic Fatty Liver Disease
Current Drug Targets Heme Oxygenase-1 in Lung Disease
Current Drug Targets Arginine Deprivation, Autophagy, Apoptosis (AAA) for the Treatment of Melanoma
Current Molecular Medicine